Robust proteome profiling of cysteine-reactive fragments using label-free chemoproteomics

George S Biggs,Emma E Cawood,Aini Vuorinen,William J McCarthy,Harry Wilders,Ioannis G Riziotis,Antonie J van der Zouwen,Jonathan Pettinger,Luke Nightingale,Peiling Chen,Andrew J Powell,David House,Simon J Boulton,J Mark Skehel,Katrin Rittinger,Jacob T Bush

DOI: https://doi.org/10.1101/2024.07.25.605137

2024-07-25

Abstract:Identifying pharmacological probes for human proteins represents a key opportunity to accelerate the discovery of new therapeutics. High-content screening approaches to expand the ligandable proteome offer the potential to expedite the discovery of novel chemical probes to study protein function. Screening libraries of reactive fragments by chemoproteomics offers a compelling approach to ligand discovery, however, optimising sample throughput, proteomic depth, and data reproducibility remains a key challenge. We report a versatile, label-free quantification proteomics platform for competitive profiling of cysteine-reactive fragments against the native proteome. This high-throughput platform combines SP4 plate-based sample preparation with rapid chromatographic gradients. Data-independent acquisition performed on a Bruker timsTOF Pro 2 consistently identified ~23,000 cysteine sites per run, with a total of ~32,000 cysteine sites profiled in HEK293T and Jurkat lysate. Crucially, this depth in cysteinome coverage is met with high data completeness, enabling robust identification of liganded proteins. In this study, 80 reactive fragments were screened in two cell lines identifying >400 ligand-protein interactions. Hits were validated through concentration-response experiments and the platform was utilised for hit expansion and live cell experiments. This label-free platform represents a significant step forward in high-throughput proteomics to evaluate ligandability of cysteines across the human proteome.

Systems Biology

What problem does this paper attempt to address?

The main objective of this paper is to develop a high-throughput, label-free quantitative chemical proteomics platform (HT-LFQ) for screening small molecule ligands targeting intracellular cysteine sites. Specifically, the research team designed a method to efficiently identify small molecule probes that interact with cysteine residues in the human proteome.

The core features of this platform include:
1. **Sample Processing Workflow**: Consistent and efficient sample cleanup using a 96-well plate format, without the need for isotope labeling.
2. **Mass Spectrometry Analysis**: Analysis using liquid chromatography-mass spectrometry (LC-MS) and data-independent acquisition (DIA) mode, which enhances the sensitivity and reproducibility of peptide detection.
3. **High Throughput and Coverage**: Analysis of a large number of cell lysate samples through short chromatographic gradients, detecting approximately 23,000 cysteine sites per run on average, with a total coverage of about 32,000 cysteine sites.
4. **Data Integrity and Reproducibility**: High data integrity and reproducibility obtained using the DIA mode, which is crucial for competitive analysis.

The research team utilized this platform to screen a library containing 80 chloroacetamide fragments and identified over 400 protein-ligand interactions in two cell lines (HEK293T and Jurkat cells). These findings provide valuable tools for understanding protein function and drug discovery. Additionally, the platform supports concentration-response experiments and structure-activity relationship studies, further enhancing its capability as an efficient chemical tool discovery method.

In summary, this study aims to address the resource-intensive and limited coverage issues of traditional small molecule ligand screening methods by providing a new chemical proteomics platform to accelerate the discovery process of new therapies.